Venture capital-backed Tandem Diabetes Care surged after its IPO on the Nasdaq exchange, which valued the medical devices company at $15 per share.
Tandem Diabetes Care, which offered 8m shares worth $120m, jumped to nearly $19 in the first two hours of trading. In October AltAssets reported that the company filed to raise $100m via an IPO.
Underwriters including BofA Merrill Lynch, Piper Jaffray, Deutsche Bank Securities and Stifel have an option to acquire a further 1.2m shares.
The company’s backers include TPG Biotechnology Partners, Kearny Venture Partners, Delphi Ventures, Domain Associates and HLM Venture Partners.
Tandem Diabetes’ products include the t:slim insulin pump, which it said is the slimmest and smallest durable insulin pump currently on the market. It is also the first insulin pump with a high resolution, colour touch screen.
Copyright © 2013 AltAssets